Analysts Offer Insights on Healthcare Companies: Fortress Biotech (NASDAQ: FBIO) and Aerpio Pharmaceuticals Inc (NASDAQ: ARPO)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Fortress Biotech (FBIOResearch Report) and Aerpio Pharmaceuticals Inc (ARPOResearch Report) with bullish sentiments.

Fortress Biotech (FBIO)

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on Fortress Biotech, with a price target of $11. The company’s shares opened today at $2.

Pantginis observed:

“Valuation and risks to price target achievement. We reiterate our Buy rating and $11 price target. Our valuation is based on our clinical net present value (NPV) model, which derives value from across Fortress’ subsidiaries. This model allows us to flex multiple assumptions affecting a drug’s potential commercial profile. Factors which could impede reaching our price target include failed or inconclusive clinical trials or inability of the company to secure adequate funding to progress its drugs through the development pathway.”

According to, Pantginis has currently no stars on a ranking scale of 0-5 stars, with an average return of -15.1% and a 29.9% success rate. Pantginis covers the Healthcare sector, focusing on stocks such as Applied Genetic Technologies, Checkpoint Therapeutics Inc, and Iovance Biotherapeutics Inc.

Currently, the analyst consensus on Fortress Biotech is a Moderate Buy with an average price target of $11.

See today’s analyst top recommended stocks >>

Aerpio Pharmaceuticals Inc (ARPO)

In a report released today, Eliana Merle from Cantor Fitzgerald reiterated a Buy rating on Aerpio Pharmaceuticals Inc, with a price target of $8. The company’s shares opened today at $1.40, close to its 52-week low of $1.20.

Merle wrote:

“. Reiterate Overweight, but lowering price target to $3 from $8. Shares are down ~70% (vs. S&P 500 flat) after the company announced the TIME-2B Phase 2b study missed its primary endpoint in diabetic retinopathy (DR). Although we have lower expectations for the program in DR, shares are currently trading close to cash, which we think overly discounts the potential for partner milestones and the ongoing glaucoma program. We see potential upside driven by: 1) a potential partnership for AKB-9778 for diabetic nephrology studies, as renal trends have been demonstrated, 2) up to $400M in milestones from in IBD and 3) initial glaucoma data in late 2019.”

According to, Merle is a 3-star analyst with an average return of 3.3% and a 43.5% success rate. Merle covers the Healthcare sector, focusing on stocks such as CymaBay Therapeutics, AnaptysBio Inc, and Galapagos NV.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Aerpio Pharmaceuticals Inc with a $9 average price target, a 542.9% upside from current levels. In a report issued on March 6, H.C. Wainwright also reiterated a Buy rating on the stock with a $10 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Leave a Reply

Your email address will not be published. Required fields are marked *